Telix Pharmaceuticals Acquires ARTMS Inc.

Telix Pharmaceuticals Acquires QSAM Biosciences

February 8, 2024

Biotechnology

Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc., adding QSAM's lead radiopharmaceutical candidate 153Sm-DOTMP (Samarium-153-DOTMP) to Telix's therapeutic pipeline. The asset expands Telix's oncology focus into bone-targeting radiopharmaceuticals with potential applications in pain management of bone metastases and osteosarcoma (including pediatric indications).

Temasek-Led €255M Investment Round in ITM Isotope Technologies Munich SE

June 5, 2023

Biotechnology

Temasek led a €255 million equity investment round in ITM Isotope Technologies Munich SE, with participation from QIA, BlackRock Alternatives, Nextech, ATHOS and Carbyne. The proceeds (mostly primary capital with a minority secondary component) will advance ITM's targeted radionuclide therapy pipeline, support late-stage clinical development of ITM-11, and expand GMP manufacturing capacity for n.c.a. 177Lu and 225Ac while bolstering commercial infrastructure.

CQ Medical Acquires Bionix Radiation Therapy Business Unit

December 1, 2025

Medical Devices

CQ Medical has acquired the Radiation Therapy business unit from Bionix, expanding CQ Medical’s patient positioning and radiotherapy marking product portfolio. The deal transfers Bionix’s radiation therapy product lines and commercial team to CQ Medical while Bionix retains its Ambulatory Care business based in Maumee, Ohio.

LIXTE Biotechnology Acquires Liora Technologies Europe Ltd

November 25, 2025

Medical Devices

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed the acquisition of Liora Technologies Europe Ltd., a UK-based developer of the LiGHT proton therapy system. The deal brings Liora's proprietary LiGHT System and Daresbury-based operations into LIXTE as a wholly owned subsidiary to expand the company's capabilities into radiotherapy and pursue joint treatment-center revenue models.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Ariceum Therapeutics Acquires Theragnostics Ltd.

June 1, 2023

Biotechnology

Ariceum Therapeutics has acquired 100% of Theragnostics Ltd., a UK-based developer of radiopharmaceutical diagnostic and therapeutic products, for $2.5 million upfront plus up to $41.5 million of milestone payments. The deal gives Ariceum late preclinical/early clinical PARP inhibitor assets, US FDA‑approved NEPHROSCAN™ (partnered with GE Healthcare) and expanded US operations, strengthening its diagnostic and therapeutic radiopharmaceutical pipeline.